Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine
17 May 2022
Firebrick Pharma’s Dr Peter Molloy and Dr Chris Rock from CMAX Clinical Research discuss with Channel 7 the start of our Phase 3 common cold trial for Nasodine® Nasal Spray. Adelaide is the first location for the trial, with sites in Victoria and South Africa to follow. If you live in South Australia or Victoria, you can visit commoncoldstudy.com to register your interest to participate in the trial.